Based on the key indicators obtained from Edesa Biotech's historical financial statements, Edesa Biotech may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, Edesa Biotech's Other Current Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3 M, whereas Total Assets are forecasted to decline to about 8.7 M. Key indicators impacting Edesa Biotech's financial strength include:
Investors should never underestimate Edesa Biotech's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Edesa Biotech's cash flow, debt, and profitability to make informed and accurate decisions about investing in Edesa Biotech.
Net Income
(7.91 Million)
Edesa
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Operating Cycle
Cash Conversion Cycle
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Change To Account Receivables
Sale Purchase Of Stock
Change To Inventory
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Investments
Change To Operating Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Property Plant And Equipment Net
Net Receivables
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Current Deferred Revenue
Non Current Liabilities Total
Intangible Assets
Common Stock Total Equity
Inventory
Common Stock
Short Term Investments
Property Plant Equipment
Accounts Payable
Net Tangible Assets
Net Invested Capital
Net Working Capital
Capital Stock
Short Long Term Debt Total
Other Liab
Capital Lease Obligations
Short Term Debt
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Total Revenue
Gross Profit
Research Development
Cost Of Revenue
Income Tax Expense
Tax Provision
Interest Income
Net Income Applicable To Common Shares
Net Income From Continuing Ops
Reconciled Depreciation
Net Interest Income
Probability Of Bankruptcy
Understanding current and past Edesa Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Edesa Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Edesa Biotech's assets may result in an increase in income on the income statement.
Please note, the presentation of Edesa Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Edesa Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Edesa Biotech's management manipulating its earnings.
Edesa Biotech Stock Summary
Edesa Biotech competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, and Transcode Therapeutics. Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada. Edesa Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Edesa Biotech's current stock value. Our valuation model uses many indicators to compare Edesa Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Edesa Biotech competition to find correlations between indicators driving Edesa Biotech's intrinsic value. More Info.
Edesa Biotech is rated # 4 in return on equity category among its peers. It is rated # 5 in return on asset category among its peers . At present, Edesa Biotech's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edesa Biotech's earnings, one of the primary drivers of an investment's value.
Edesa Biotech Systematic Risk
Edesa Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Edesa Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Edesa Biotech correlated with the market. If Beta is less than 0 Edesa Biotech generally moves in the opposite direction as compared to the market. If Edesa Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Edesa Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Edesa Biotech is generally in the same direction as the market. If Beta > 1 Edesa Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Edesa Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Edesa Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Edesa Biotech growth as a starting point in their analysis.
Price Earnings To Growth Ratio
1.71
At present, Edesa Biotech's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Edesa Biotech November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Edesa Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Edesa Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Edesa Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Edesa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Edesa Biotech's daily price indicators and compare them against related drivers.
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.